Clinical trial NCT06025240: Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Official title: Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Kidney Transplant
Renal Transplant Failure
Kidney Transplant Rejection
Frailty
Kidney Transplant; Complications
Transplant Dysfunction
Diagnosis
Renal Transplant
Keywords: kidney transplant
novel biomarkers
post-transplant antibodies
HLA-specific antibodies
donor specific antibodies
transplant in older age
machine learning
predictive models
rejection
Lead sponsor: Liverpool University Hospitals NHS Foundation Trust
Sponsor class: OTHER_GOV
Collaborators: name: Kidney Research United Kingdom
First posted: 2023-09-06
Enrollment: 282
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. cf-DNA arm: Patients who have undergone a "high risk" renal transplant in our unit within the last 6-12 months will be retrospectively recruited to the study.
2. Older Age Immunological Events: Post-transplant patients prospectively recruited, irrespective of age, undergoing transplant to determine the overall frequency of immunological events and de novo HLA specific antibody formation. We will collect data on clinical outcomes and would look to compare the \<60s with those 60 or older looking for a difference in immunological events beteween the 2 groups.
3. Predictive models: A subset of the cohort of recruits to the immunological factors in older age study will be used to determine machine learning algorithms of predictive factors for the development of de novo donor specific antibody.

Brief summary: The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.

Detailed description: Donor-derived cell-free DNA (dd-cfDNA)

Post-transplant monitoring for acute rejection in most centres, focuses on identification of a deterioration in graft function which may be totally asymptomatic. The current best practice to investigate a suspected rejection are renal graft biopsy with appropriate staining for complement component C4d and a serum single antigen bead (SAB) testing. This reactive approach to assessing and monitoring rejection, mainly driven by serial assessments of renal function to determine response to treatment, avoids the need for multiple invasive diagnostic tests such as biopsies, but it poses the risk of missing the early detection and treatment of rejection prior to an objective decline in function. A "creeping creatinine", where there are small but sustained increases in creatinine at sequential visits is relatively common and by the time a deterioration consistent with rejection is observed there can already have been significant tissue damage.

Donor-derived cell-free DNA (dd-cfDNA) has been described as a useful biomarker for graft injury secondary to rejection which can be evident in blood weeks to months prior to histological evidence of graft injury. dd-cfDNA levels are high in the immediate post-operative phase, although there is a sharp drop off to low baseline levels after a few days to two weeks making it a useful biomarker in all but the earliest rejection episode. Levels are much higher in antibody mediated rejection (ABMR) when compared to cellular rejection offering improvements in sensitivity when considering ABMR alone (85%) versus rejection of all aetiology (59%). The investigators believe it is important to correlate the findings of the dd-cfDNA sample with the other tests described, so that observations about the percentage dd-cfDNA found in different pathologies and the overall frequency of positive results can be made.

Immunological Factors in Older Age Renal Transplant and Longitudinal Donor Specific Antibodies (DSA) study

Older patients who undergo kidney transplant (KT) have better survival than those who remain on the waiting list. Nevertheless, outcomes are inferior to younger recipients and KT is often felt to be a predominantly quality of life intervention for older patients. Frailty may have a beneficial influence on the risk of post-transplant adverse immunological events and rejection episodes. If transplanted with good quality organs (all barring elderly deceased after circulatory death - DCD grafts), older kidney transplant recipients will have fewer rejection episodes than younger counterparts. The investigators conducted a retrospective cohort study of the outcomes for older age transplant recipients (\>60) locally, to compare results before and after the change in allocation system which coincides with the COVID-19 pandemic. In this study, the investigators observed less favourable HLA-mismatching, a higher rate of re-intervention (operative or interventional radiology), higher rates of tertiary centre readmissions and higher 1-year mortality rates.

The previous post-transplant HLA-specific antibody work examined only the first positive sample post-transplant independent of pre-transplant sensitisation status. The investigators, thus, propose prospectively recruiting patients, irrespective of age, undergoing transplant to determine the overall frequency of immunological events and de novo HLA specific antibody formation. Given the importance of early detection and intervention of antibody mediated processes and optimising treatment protocols for frail patients, the investigators aim to expand the research interest in post-transplant antibody monitoring. The investigators, thus, propose prospectively recruiting patients, irrespective of age, undergoing transplant to determine the overall frequency of immunological events and de novo HLA specific antibody formation. Data on clinical outcomes will be collected and the investigators would look to compare the \<60s with those 60 or older patients undergoing kidney transplant.

Determining Predictive Models for Post-transplant HLA-specific Antibody Formation

As an adjunct to the proposed study looking at the influence of age on immunological events, the investigators aim to examine the cohort as a whole to determine the differential clinical outcomes for patients with and without de novo HLA-specific antibody over time. An important part of this arm of the study will be to determine predictive models using machine learning methodology to determine those most at risk for the development of de-novo HLA specific antibody post-transplant.

Eligibility criteria: Inclusion Criteria:

1. cf-DNA arm:

   * Adult patients transplanted within 6-12 months (retrospective recruitment)
   * Patients admitted for renal transplant or within the first 6 months following transplant (prospective recruitment)
   * Patients must have capacity to provide informed consent
   * Patients must have received a high-risk transplant defined as level 4 mismatch, cRF \>20, second or subsequent transplant, ABO or HLA incompatible
2. Older Age Immunological Events:

   - Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant
3. Predictive models:

   * Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant
   * Unsensitized pre-transplant

Exclusion Criteria:

1. cf-DNA arm:

   * Transplanted for longer than 12 months;
   * Low risk transplants;
   * Patients lacking capacity;
2. Older Age Immunological Events:

   * Patients lacking capacity
   * Patients transplanted longer than 2 weeks
3. Predictive models:

   * Sensitised patients
   * Patients lacking capacity
   * Patients transplanted longer than 2 weeks

Primary outcomes:
measure: dd-cf DNA
timeFrame: 6-12 months post-transplant
measure: Immunological events in older age
timeFrame: through study completion, an average of 1 year
measure: Longitudinal DSA monitoring
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
measure: Occurrence of UTIs, viral reactivation and structural transplant abnormalities in high-risk post-transplant patients at 6-12 months
timeFrame: 6-12 months
measure: Association of cell free DNA result and any identified pathology (DSA, UTI, viral infection)
timeFrame: through study completion, an average of 1 year
measure: Comparison of graft and patient survival to 12 months in the over 60s and <60
timeFrame: through study completion, an average of 1 year
measure: Comparison of renal function, viral reactivation, readmission and reoperation rates between the 2 age groups (over 60s and <60)
timeFrame: through study completion, an average of 1 year
measure: Comparison of post-transplant complications (utilising the Clavien-Dindo classification of surgical complications) between patients developing de novo HLA specific antibody and those who do not, using machine learning models
timeFrame: through study completion, an average of 1 year
measure: Comparison of post-transplant graft and patient survival between patients developing de novo HLA specific antibody and those who do not, using machine learning models
timeFrame: through study completion, an average of 1 year
Other outcomes:
Locations:
city: Liverpool
country: United Kingdom
facility: Liverpool University Hospitals NHS Foundation Trust
state: Merseyside
Study officials:
affiliation: Liverpool University Hospitals NHS Foundation Trust
name: Petra M Goldsmith, MBBChir PhD FRCS
role: STUDY_DIRECTOR
affiliation: Liverpool University Hospitals NHS Foundation Trust
name: George E Nita, MBChB MSc MRCSEd
role: PRINCIPAL_INVESTIGATOR
References: